Quoin Pharmaceuticals
QNRX
20 hedge funds and large institutions have $6.29M invested in Quoin Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 9 increasing their positions, 3 reducing their positions, and 3 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 3
8.61% less ownership
Funds ownership: 73.3% → 64.7% (-8.6%)
9% less funds holding
Funds holding: 22 → 20 (-2)
20% less capital invested
Capital invested by funds: $7.82M → $6.29M (-$1.53M)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$788K |
| 2 |
Millennium Management
New York
|
+$195K |
| 3 |
Barclays
London,
United Kingdom
|
+$109K |
| 4 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$103K |
| 5 |
DIG
Dauntless Investment Group
Etna,
New Hampshire
|
+$99.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Centiva Capital
New York
|
-$396K |
| 2 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
-$283K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$215K |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$16.9K |
| 5 |
GI
GAMMA Investing
Foster City,
California
|
-$6.91K |
QNRX Hedge Fund Activity: Q2 2026 in Review
20 of the 8,329 institutional investors tracked by Wall St. Rank reported a position in Quoin Pharmaceuticals (QNRX) for Q2 2026, worth a combined $6.29M — down 20% from $7.82M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of QNRX and 1 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 9 added.
The largest buyer was Stonepine Capital Management, adding an estimated $788K. The largest seller was Centiva Capital, exiting entirely with an estimated $396K sold.
- 20 institutional investors held Quoin Pharmaceuticals (QNRX) as of Q2 2026, down from 22 in Q1 2026.
- Funds reported $6.29M of Quoin Pharmaceuticals stock for Q2 2026, down 20% quarter-over-quarter.
- 1 fund opened new Quoin Pharmaceuticals positions in Q2 2026 and 3 closed out, a net change of -2 holders.
- The largest Quoin Pharmaceuticals buyer in Q2 2026 was Stonepine Capital Management, an estimated $788K added.
- The largest Quoin Pharmaceuticals seller in Q2 2026 was Centiva Capital, an estimated $396K sold.
Based on aggregated 13F filings for Q2 2026.